A new user cohort study of 109 504 gout patients, achieving a serum urate level less than 6 mg/dL, was associated with a significantly lower risk of cardiovascular events.

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with unprecedented specificity.

I recently attended a fascinating lecture by Dr. Anisha Dua on progress in the diagnosis and treatment of large-vessel vasculitis, with a focus on giant cell arteritis (GCA) and Takayasu's arteritis. She opened with what felt like the most honest “state of the union” slide you can show a room full of rheumatologists: steroid burden is still enormous.

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Do shoes make a difference in osteoarthritis (OA)? Common advice often suggests that stable supportive shoes can improve arthritis symptoms in the knee, but does this apply to hip osteoarthritis?

Dry eye rates upwards of 20% were seen across nine common autoimmune diseases other than Sjögren's, most often in rheumatoid arthritis (39.3%) with Crohn's disease bringing up the rear (23.0%), according to Chi-Chin Sun, MD, PhD, of Chang Gung Memorial Hospital in Keelung, Taiwan, and colleagues.

A report in The Lancet Diabetes & Endocrinology suggested that 3 months of romosozumab (ROMO) followed by denosumab is as effective at increasing hip bone mineral density (BMD) as the standard 12-month course.

An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost effectiveness and clinical utility of early BEL initiation in active lupus patients.

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.